Natalizumab modulates the humoral response against HERV-Wenv73-88 in a follow-up study of Multiple Sclerosis patients
详细信息 查看全文
- 作者：Giannina Arrua ; Elisa Caggiua ; Stefania Leonib ; Giuseppe Mamelia ; Maura Pugliattib ; Gian Pietro Sechib ; Leonardo A. Sechia ; sechila@uniss.it" class="auth_mail" title="E-mail the corresponding author
- 关键词：Multiple Sclerosis ; Natalizumab therapy ; HERV-Wenv ; Epstein Barr Virus (EBV) ; Mycobacterium avium ss. paratuberculosis (MAP) ; Antibodies ; ELISA
- 刊名：Journal of the Neurological Sciences
- 出版年：2015
- 出版时间：15 October 2015
- 年：2015
- 卷：357
- 期：1-2
- 页码：106-108
- 全文大小：325 K
文摘
- •
Ab response against EBNA1, MAP106c, MBP and HERV-Wenv was evaluated in MS patients.
- •
No difference was observed during natalizumab treatment for EBNA1, MAP106c, and MBP.
- •
Difference in the Ab response was observed for HERV-Wenv during natalizumab exposure.
- •
Natalizumab treatment reduces Ab production against HERV-Wenv in MS patients.